Having trouble accessing articles? Reset your cache.

Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

Kite plans marketing applications for CD19 CAR T on pivotal MCL data
Kite Pharma Inc. reported a 93% best objective response rate including a 67% complete response rate -- secondary endpoints -- in 60 evaluable relapsed or refractory mantle cell lymphoma patients who received a single infusion

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE